This document has been prepared by Double Bond Pharmaceutical for the purpose of summarising current scientific literature and providing a short assessment of the challenges and therapeutic opportunities in glioblastoma treatment. 13th August 2025. Glioblastomas’ significant heterogeneity complicates diagnosis in an era of increasing reliance on genotyping, as traditional biopsies may provide an incomplete genetic snapshot of the tumour. This same complexity also limits the effectiveness of targeted therapies. In contrast, broad-acting agents, such as the locally delivered SI-053, offer a more generalised approach. By targeting the fundamental process of DNA replication, SI-053 is designed to suppress growth across diverse tumour subvariants, overcoming limitations posed by genetic heterogeneity and the blood-brain barrier.
Authors: Double Bond Pharmaceutical
Keywords: tumor heterogeneity, genotyping, SI-053
Contact information
Full Company Name:
Double Bond Pharmaceutical International AB (publ)
Corporate identity:
556991-6082
Stock short name:
DBP B
Share ISIN code:
SE0007185525
For more info, contact
Igor Lokot, CEO
Homepage:
E-mail:
Blog:
Follow us on:
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.